Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for presentation at a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, to be held April 14-19, 2023 in Orlando, Fl.
https://finance.yahoo.com/news/corbus-pharmaceuticals-data-crb-601-203500501.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.